HSP90

Three Journal of Pharmaceutical Analysis Studies Explore the Use of Traditional Chinese Medicine for Various Diseases

Retrieved on: 
Friday, January 26, 2024
DMY, Microangiopathy, Neoplasm, VEGF, NAFLD, Radiation, Fe, ATGL, Disease, Lung cancer, TCM, DR, Risk, Quality of life, Diabetic retinopathy, Journal, Nano, Traditional Chinese medicine, Liver, Noetics, Protein, HSP90, CDC37, Non-alcoholic fatty liver disease, Iron

XI'AN, China, Jan. 26, 2024 /PRNewswire/ -- Despite demonstrating significant clinical efficacy against various diseases, the widespread use of Traditional Chinese Medicine (TCM) is still limited.

Key Points: 
  • XI'AN, China, Jan. 26, 2024 /PRNewswire/ -- Despite demonstrating significant clinical efficacy against various diseases, the widespread use of Traditional Chinese Medicine (TCM) is still limited.
  • To address this gap, a new issue of the Journal of Pharmaceutical Analysis presents three independent studies which assessed the potency of TCM-based compounds for various human diseases, along with their molecular mechanisms of action.
  • Oridonin (ORI), a TCM derived from the Chinese herb Rabdosia rubescens, exhibits anti-inflammatory effects.
  • These studies provide a scientific basis for the development of TCM-based compounds into effective targeted therapies for various diseases.

Three New Articles in the Journal of Pharmaceutical Analysis Demonstrate the Potential of Natural Compounds to Treat Gastrointestinal Disorders

Retrieved on: 
Tuesday, November 28, 2023
Hepatitis, MEFV, Dave's Picks Volume 13, Hope, Pneumonia, Liver, HSP90, Panax notoginseng, Macrophage, Mouse, Journal, Colitis, Metabolism, Ulcerative colitis, Ethanol, GI, NLRP3, SNZ, ALD, UC, JPA, Pharmaceutical industry

XI'AN, China, Nov. 28, 2023 /PRNewswire/ -- Chronic gastrointestinal (GI) disorders are becoming increasingly common throughout the world, but many of them still lack effective treatment. Researchers have now turned to natural compounds, such as those present in traditional medicines, to search for potential drug candidates for difficult-to-treat diseases. The latest issue of the Journal of Pharmaceutical Analysis (JPA) features three articles that report promising findings and could pave the way to treatments for complex diseases affecting the liver and intestine. 

Key Points: 
  • Researchers have now turned to natural compounds, such as those present in traditional medicines, to search for potential drug candidates for difficult-to-treat diseases.
  • The latest issue of the Journal of Pharmaceutical Analysis (JPA) features three articles that report promising findings and could pave the way to treatments for complex diseases affecting the liver and intestine.
  • The article was available online in July 2023 and published in Volume 13, Issue 9 of JPA in September 2023 .
  • Moreover, Rk2 also restored intestinal barrier function by enhancing NLPR6 signaling in the intestine, demonstrating its multifaceted therapeutic potential.

MC2 Therapeutics Announces Positive Phase 2a Results of Novel HSP90 Inhibitor for Hidradenitis Suppurativa Presented at EADV

Retrieved on: 
Wednesday, October 11, 2023
Inflammation, Aarhus University Hospital, DLQI, Safety, Hurley, Hidradenitis suppurativa, Patient, Therapy, HSP90, CMO, MC2, Clinical trial, News, HS, Pharmaceutical industry, Medical imaging

The single center, Phase 2a, clinical trial conducted at Aarhus University Hospital, Denmark evaluated the efficacy and safety of MC2-32 in patients with moderate to severe (Hurley stage 2 or 3) HS.

Key Points: 
  • The single center, Phase 2a, clinical trial conducted at Aarhus University Hospital, Denmark evaluated the efficacy and safety of MC2-32 in patients with moderate to severe (Hurley stage 2 or 3) HS.
  • 15 patients were recruited for the study and randomized 2:1, to 16 weeks oral treatment with 250 mg MC2-32 once daily or placebo.
  • The study was a Phase 2a proof-of-concept study and not designed to obtain statistical significance.
  • Joining our strong portfolio of immunology and inflammation treatments in development and on the market, MC2 Therapeutics is on its way to becoming an emerging force in the field.”

BostonGene Announces Publication in Cancer Research

Retrieved on: 
Tuesday, November 2, 2021
Science, Software, Biotechnology, Research, Pharmaceutical, Oncology, Health, Technology, B-cell lymphoma, DLBCL, Cancer research, MD, Research, MYC, Cancer, Association, Neoplasm, Patient, HSP90, Weill Cornell Medicine, Lymphoma, Sandra, Maintenance, Standard of care, Economics, Biomarker, American Association, American Association for Cancer Research, Associate, Enzyme, AI, Aggressive lymphoma, Pharmaceutical industry, Medical imaging

BostonGene Corporation, a biomedical software company committed to defining optimal precision medicine-based therapies for cancer patients today announces a new publication in the peer-reviewed scientific journal Cancer Research, a journal of the American Association for Cancer Research.

Key Points: 
  • BostonGene Corporation, a biomedical software company committed to defining optimal precision medicine-based therapies for cancer patients today announces a new publication in the peer-reviewed scientific journal Cancer Research, a journal of the American Association for Cancer Research.
  • This study evaluated the role of oncogenic HSP90 in regulating cytosolic metabolic pathways in proliferating B-cell lymphoma cells.
  • We are pleased to support Weill Cornell Medicine in their research efforts to find optimal therapeutic treatments for patients with DLBCL.
  • Through these comprehensive analyses, BostonGene Tumor PortraitTM Tests generate a personalized roadmap for therapeutic decision-making for each cancer patient.

Tarveda Therapeutics Announces Data from Phase 2 Trial of PEN-221 to Be Presented at NANETS 2021 Multidisciplinary NET Virtual Symposium

Retrieved on: 
Monday, November 1, 2021
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Radionuclide, DM1, Neoplasm, Therapy, Patient, SSTR2, HSP90, Pharmaceutical industry, Medical imaging

Tarvedas Pentarin miniature drug conjugates are designed to deeply penetrate solid tumors, selectively bind to the desired tumor targets and accumulate their anti-cancer payloads directly in tumor cells.

Key Points: 
  • Tarvedas Pentarin miniature drug conjugates are designed to deeply penetrate solid tumors, selectively bind to the desired tumor targets and accumulate their anti-cancer payloads directly in tumor cells.
  • The payload is retained and then released over time causing the anti-cancer payload to become active in the tumor.
  • Tarvedas first clinical program, PEN-866, is the initial candidate from its Heat Shock Protein 90 (HSP90) binding miniature drug conjugate platform.
  • PEN-866 has commenced its Phase 2a trial in various types of solid tumors.

Aston Sci. Announces the Study Results of Two Therapeutic Cancer Vaccines at the 2021 Society for Immunotherapy of Cancer (SITC) Annual Meeting

Retrieved on: 
Wednesday, October 27, 2021
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Aston, Safety, Geriatrics, Breast cancer, Research, Peptide, Recurrence, Diagnosis, Technology, Cancer, Disease, Industry, Immunotherapy, NH Investment & Securities, Immunology, Patient, KOSDAQ, Society, Ministry, HSP90, HLA, Clinical trial, CEO, Epitope, IND, American Society of Clinical Oncology, SITC, Ministry of Food and Drug Safety, ASCO, Pharmaceutical industry

Aston Sci., a portfolio model biopharmaceutical company, announced that the study results of its therapeutic cancer vaccine pipelines, AST-301 and AST-021p, will be presented at the Society for Immunotherapy of Cancer(SITC) in November.

Key Points: 
  • Aston Sci., a portfolio model biopharmaceutical company, announced that the study results of its therapeutic cancer vaccine pipelines, AST-301 and AST-021p, will be presented at the Society for Immunotherapy of Cancer(SITC) in November.
  • At the 2021 American Society of Clinical Oncology (ASCO) in June, Aston Sci.
  • demonstrated the medical efficacy and long-term safety of AST-301 through the results from phase 1 clinical trials on 66 patients with HER2-positive advanced breast cancer.
  • AST-301 is currently under IND review by the Ministry of Food and Drug Safety for subsequent clinical trials.

Tarveda Therapeutics to Present at Solebury Trout/BMO Private Company Showcase

Retrieved on: 
Wednesday, October 13, 2021
Banking, Research, Other Health, General Health, Professional Services, Pharmaceutical, Oncology, Science, Other Professional Services, Biotechnology, Finance, Health, Other Science, Radionuclide, Neoplasm, HSP90, Patient, Therapy, Solebury Township, Bucks County, Pennsylvania, Pharmaceutical industry, Medical imaging

Tarveda Therapeutics, Inc. , a clinical stage biopharmaceutical company developing a new class of potent and selective precision oncology medicines, which it refers to as Pentarin miniature drug conjugates, today announced that Brian Roberts, President and Chief Executive Officer, will present virtually at the Solebury Trout/BMO Fall 2021 Private Company Showcase on Thursday, October 14.

Key Points: 
  • Tarveda Therapeutics, Inc. , a clinical stage biopharmaceutical company developing a new class of potent and selective precision oncology medicines, which it refers to as Pentarin miniature drug conjugates, today announced that Brian Roberts, President and Chief Executive Officer, will present virtually at the Solebury Trout/BMO Fall 2021 Private Company Showcase on Thursday, October 14.
  • Tarvedas Pentarin miniature drug conjugates are designed to deeply penetrate solid tumors, selectively bind to the desired tumor targets and accumulate their anti-cancer payloads directly in tumor cells.
  • The payload is retained and then released over time causing the anti-cancer payload to become active in the tumor.
  • Tarvedas first clinical program, PEN-866, is the initial candidate from its Heat Shock Protein 90 (HSP90) binding miniature drug conjugate platform.

Tarveda Therapeutics and SciClone Pharmaceuticals Expand Partnership by Entering into a License Agreement for HSP90-PI3K Miniature Drug Conjugates in Greater China

Retrieved on: 
Thursday, September 16, 2021
Biotechnology, Pharmaceutical, Health, Oncology, Therapy, Achievement, Holding, Patient, Radionuclide, Infection, Company, HSP90, Neoplasm, Partnership, Organization, Research, PI3K, Fine chemical, Pharmaceutical industry

Further, Tarveda will be eligible to receive royalties based on net sales of the licensed product portfolio in Greater China.

Key Points: 
  • Further, Tarveda will be eligible to receive royalties based on net sales of the licensed product portfolio in Greater China.
  • We are excited to expand our relationship with SciClone Pharmaceuticals, said Brian Roberts, President and Chief Executive Officer of Tarveda.
  • SciClone Pharmaceuticals has proven to be a reliable and outstanding partner with deep product, regulatory and commercialization experience in Greater China and we are thrilled to broaden our partnership beyond PEN-866 to also include our pre-clinical PI3K miniature drug conjugates.
  • Since March 2020, SciClone and Tarveda have established a positive relationship of favorable interactions and mutual trust through co-developing PEN-866.